181 related articles for article (PubMed ID: 30378479)
1. Aim for the Readers! Bromodomains As New Targets Against Chagas' Disease.
Alonso VL; Tavernelli LE; Pezza A; Cribb P; Ritagliati C; Serra E
Curr Med Chem; 2019; 26(36):6544-6563. PubMed ID: 30378479
[TBL] [Abstract][Full Text] [Related]
2. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
Moraes CB; Giardini MA; Kim H; Franco CH; Araujo-Junior AM; Schenkman S; Chatelain E; Freitas-Junior LH
Sci Rep; 2014 Apr; 4():4703. PubMed ID: 24736467
[TBL] [Abstract][Full Text] [Related]
3. The chemotherapy of chagas' disease: an overview.
Paulino M; Iribarne F; Dubin M; Aguilera-Morales S; Tapia O; Stoppani AO
Mini Rev Med Chem; 2005 May; 5(5):499-519. PubMed ID: 15892691
[TBL] [Abstract][Full Text] [Related]
4. Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds.
Cerecetto H; González M
Mini Rev Med Chem; 2008 Nov; 8(13):1355-83. PubMed ID: 18991753
[TBL] [Abstract][Full Text] [Related]
5. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.
Beltran-Hortelano I; Perez-Silanes S; Galiano S
Curr Med Chem; 2017 May; 24(11):1066-1138. PubMed ID: 28025938
[TBL] [Abstract][Full Text] [Related]
6. [The chemotherapy of Chagas disease].
Stoppani AO
Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
[TBL] [Abstract][Full Text] [Related]
7. Proteomic and bioinformatic analysis of Trypanosoma cruzi chemotherapy and potential drug targets: new pieces for an old puzzle.
Sadok Menna-Barreto RF; Belloze KT; Perales J; Silva FP
Curr Drug Targets; 2014 Mar; 15(3):255-71. PubMed ID: 24041335
[TBL] [Abstract][Full Text] [Related]
8. Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives.
Ogindo CO; Khraiwesh MH; George M; Brandy Y; Brandy N; Gugssa A; Ashraf M; Abbas M; Southerland WM; Lee CM; Bakare O; Fang Y
Bioorg Med Chem; 2016 Aug; 24(16):3849-55. PubMed ID: 27345756
[TBL] [Abstract][Full Text] [Related]
9. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
10. Essential Bromodomain
Pezza A; Tavernelli LE; Alonso VL; Perdomo V; Gabarro R; Prinjha R; Rodríguez Araya E; Rioja I; Docampo R; Calderón F; Martin J; Serra E
ACS Infect Dis; 2022 May; 8(5):1062-1074. PubMed ID: 35482332
[No Abstract] [Full Text] [Related]
11. Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease.
Osorio-Méndez JF; Cevallos AM
Front Cell Infect Microbiol; 2018; 8():439. PubMed ID: 30666299
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease.
Gaspar L; Coron RP; KongThoo Lin P; Costa DM; Perez-Cabezas B; Tavares J; Roura-Ferrer M; Ramos I; Ronin C; Major LL; Ciesielski F; Pemberton IK; MacDougall J; Ciapetti P; Smith TK; Cordeiro-da-Silva A
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006180. PubMed ID: 29357372
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of Chagas' disease: status and new developments.
Cerecetto H; González M
Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
[TBL] [Abstract][Full Text] [Related]
14. Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development.
Jeffers V; Yang C; Huang S; Sullivan WJ
Microbiol Mol Biol Rev; 2017 Mar; 81(1):. PubMed ID: 28077462
[TBL] [Abstract][Full Text] [Related]
15. Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi.
de Souza VA; da Silva R; Pereira AC; Royo Vde A; Saraiva J; Montanheiro M; de Souza GH; da Silva Filho AA; Grando MD; Donate PM; Bastos JK; Albuquerque S; e Silva ML
Bioorg Med Chem Lett; 2005 Jan; 15(2):303-7. PubMed ID: 15603944
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of Chagas disease.
Urbina JA
Curr Pharm Des; 2002; 8(4):287-95. PubMed ID: 11860367
[TBL] [Abstract][Full Text] [Related]
17. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
18. Structural modelling and comparative analysis of homologous, analogous and specific proteins from Trypanosoma cruzi versus Homo sapiens: putative drug targets for chagas' disease treatment.
Capriles PV; Guimarães AC; Otto TD; Miranda AB; Dardenne LE; Degrave WM
BMC Genomics; 2010 Oct; 11():610. PubMed ID: 21034488
[TBL] [Abstract][Full Text] [Related]
19. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
[TBL] [Abstract][Full Text] [Related]
20. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model.
Valle-Reyes JS; Melnikov V; Dobrovinskaya O; Rodriguez-Hernández A; Wookee-Zea C; Pimientel-Rodrigez V; Rueda-Valdovinos G; Delgado-Enciso I; López-Lemus UA; Espinoza-Gómez F
Exp Parasitol; 2017 Jan; 172():44-50. PubMed ID: 28011170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
